Прорыв в лечении детского рака: мРНК-вакцина сократила опухоли нейробластомы на 70%

For the first time, researchers have demonstrated that an mRNA vaccine can effectively target neuroblastoma, the deadliest childhood cancer. Published in Molecular Therapy Oncology, the study from RCSI University of Medicine and Health Sciences reports a 70% reduction in tumor volume and a 10–11 day delay in tumor development in preclinical models . The vaccine uses a modular "LEGO brick" platform that could be rapidly adapted to other cancers.

Key Findings: First Preclinical Proof-of-Concept

Led by Dr. Olga Piskareva, the RCSI team delivered the first-ever preclinical evidence of an mRNA vaccine targeting neuroblastoma . In a subcutaneous murine model of MYCN-amplified neuroblastoma, the vaccine produced:

• 70% tumor volume reduction compared to controls .
• 10–11 day delay in tumor development in vaccinated mice .
• Antigen-specific immune response: Immunization generated significant increases in IFN-γ and IL-2 from splenocytes, and TNF-α from CD4+ and CD8+ T cells, confirming a targeted cellular immune response .

How the Vaccine Works: RALA Nanoparticles and the GPC2 Target

The vaccine delivers mRNA encoding Glypican 2 (GPC2)—a tumor-associated antigen heavily expressed on neuroblastoma cells—using self-assembling cationic RALA peptide nanoparticles . RALA nanoparticles have been previously studied for DNA vaccination, including in prostate cancer models, where they successfully delivered pDNA and elicited tumor-specific immune responses . This mRNA platform represents a significant advancement over earlier nanoparticle-based approaches for neuroblastoma, which had explored bacterial-membrane-coated nanoparticles combined with radiation to achieve tumor regression .

Importantly, GPC2 is overexpressed across multiple adult and pediatric cancer types, meaning the platform is designed for rapid adaptation to other GPC2-expressing cancers .

The Modular "LEGO Brick" Platform

Dr. Piskareva described the technology as "like LEGO bricks" —different components can be swapped to tailor the vaccine with high precision for individual patients or different tumor targets . This modularity is a key differentiator from existing mRNA cancer vaccines, which have shown most clinical progress in melanoma, pancreatic cancer, and non-small cell lung cancer, largely using personalized neoantigen approaches or fixed antigen panels . By targeting a shared antigen (GPC2) rather than patient-specific mutations, this platform could be developed as an off-the-shelf therapy for a defined patient population.

Why It Matters: The Urgent Need for New Neuroblastoma Treatments

Neuroblastoma accounts for 15% of childhood cancer deaths, and 80% of high-risk patients show no significant response to current standard therapies . Recurrent disease is especially treatment-resistant. Prior to this study, no experimental or clinical trial data on an mRNA vaccine for neuroblastoma had been published . While mRNA vaccines have shown promise in brain cancers like glioblastoma, and nanoparticle systems are being actively investigated for crossing the blood-brain barrier , this is the first direct evidence that an mRNA vaccine can target neuroblastoma specifically.

Early Stage, But a Clear Milestone

As Dr. Piskareva stated: "We are at the beginning of the mRNA vaccine development road, but the first milestone has been successfully completed." The findings are from murine models only, and significant work remains before human trials can begin. Key next steps will include toxicological assessment—similar to ongoing work with other mRNA cancer vaccines that are being evaluated in rats and pigs —and optimization of the nanoparticle delivery system for clinical use.

Funding and Collaboration

The study was a collaboration with the School of Pharmacy at Queen's University Belfast and funded by the Irish Research Council, the Higher Education Authority, the Health Research Board, and The Conor Foley Neuroblastoma Cancer Research Foundation . The full open-access paper is available in Molecular Therapy Oncology (DOI: 10.1016/j.omton.2026.201244) .